

ARCHOS launches Medical Devices Venture

Paris - June 2nd 2021– ARCHOS announces the launch of Medical Devices Venture - MDV.

Set up as a holding structure, MDV will develop a diverse portfolio of participations in the field of Med Tech. MDV relies on the ARCHOS Group experience in the industrialization of electronic products (both in consumer markets with Archos or professional verticals with Logic Instrument). It takes majority stakes in new companies created in joint collaboration with both SATT entities (Society for the Acceleration of Technology Transfer) and researchers who invent new technologies. The goal of SATTs is to promote French research work (through maturation programs and financing of prototypes' development or clinical studies) and to validate the market-product fit of researchers' inventions. MDV brings its long-standing industrial know-how as well as its product launch experience and its network to support these structures' solutions' Go to Market and further development.

A promising market attracting investment funds

The "Med Tech" market represents a turnover of 500 billion US dollars worldwide - 70% of which is in Europe and the USA. Its 5% CAGR is driven by the need of improving health throughout all stakeholders from the quality of care and engagement requested by patients, effectiveness targeted by care providers (anticipation, prevention) or the need from Governments to improve access to healthcare while controlling its costs.

The sector was financed to the tune of € 9 billion in Europe in 2020 by investment funds attracted by the following differentiators:

- Innovations are usually addressable to a global market.
- Government policies heavily support innovations improving healthcare programs efficiency.
- Large groups operating in this field, always on the look-out for new innovations, are committed to strong acquisition strategies, in addition to their internal R&D efforts, to support their growth or complement their products and services portfolio.

DEXTRAIN: a first company in the field of neuro-rehabilitation

MDV's first investment is DEXTRAIN, which solution, resulting from innovative research carried out at the Paris Institute of Psychiatry and Neuroscience (Inserm U1266, University of Paris), improves both the independence and quality of life of patients having suffered a stroke, and will expand into clinical protocol on mobile solutions for patients with neurodegenerative diseases.

Globally, around 11 million people have survived a stroke, 60% of which have more or less significant neurological disorders in the form of motor, language, sensory or visual deficits. The devices developed by DEXTRAIN provide a unique analysis of patients' manual dexterity, often impacted after a stroke. Many other neurological conditions can lead to impaired manual dexterity (multiple sclerosis, traumatic brain injury, Parkinson's disease). Despite the development of training robots for arm and shoulder movements, specific dexterity training tools are still lacking for caregivers and patients.

ARCHOS

DEXTRAIN is currently developing two products:

The Dextrain Manipulandum



combines ultra-precise measurement of finger strength with specific neuroscience-inspired tasks, enabling unparalleled multidimensional characterization of manual dexterity. This new technology was designed to improve the treatment of patients with manual dexterity deficit following a stroke. Up to 50% of stroke survivors have impaired hand and finger function. This deficit limits daily autonomy and has a heavy impact on the quality of life. The ergonomics of the device and the rehab exercises have been improved throughout the scientific projects and numerous tests carried out with patients. Clinical

trials have been conducted to test the feasibility of the several publications that have provided new information on dexterity disorders, after strokes, that often go undetected in the clinic. The Dextrain Manipulandum detects for example the lack of independence of the fingers (not detected in the clinic), which is harmful for writing, using the cell phone or buttoning a shirt, etc. "The advantage of the Dextrain Manipulandum is that it provides an accurate and comprehensive assessment of dexterity and also enables training targeted at each individual's deficit with intensive and motivating exercises.", Pavel Lindberg, co-inventor and president of the scientific council of Dextrain.

The Dextrain Home Care



assessment for dexterity screening and dexterity training, for example, in the patient room at the hospital or at home. The goal is to offer continuous care, in rehabilitation services, in outpatient clinics and in patients' homes, thus maximizing the potential for recovery.

Rapid screening for dexterity disorders also paves the way for the early detection of progressive neurological diseases such as neurodegenerative disorders (Alzheimer's or Parkinson's disease) or neurodevelopmental disorders such as schizophrenia. Current research is investigating how early dexterity profiling, combined with analysis employing machine learning, can aid in the prognosis and prevention of disease development.

MDV perspectives

During the 3rd quarter of 2021, MDV's 2nd investment will be unveiled in the dermatology segment. In order to accelerate its development, MDV intends to prepare for its IPO before the end of 2021.

Contact

Loïc POIRIER – CEO – poirier@archos.com

About Archos

ARCHOS, a pioneer in mobile solutions, has constantly revolutionized this market both in the consumer electronics sector and in B to B with its subsidiary Logic Instrument. The French brand was the first to offer Google Android tablets in 2009. Today, ARCHOS designs and democratizes products with high innovation value and in 2021 created a MedTech division, Medical Devices Venture, which will bring together several start-up. With a head office in France, offices in Europe and Asia, ARCHOS asserts itself as a key pan-European player, listed on the Euronext Growth Paris market, ISIN Code: FR0000182479. www.archos.com